Navigation Links
New treatment option for patients with chronic hepatitis C
Date:5/28/2009

A new combination therapy of daily consensus interferon (CIFN) and ribavirin is effective for some people with chronic hepatitis C (HCV) who do not respond to standard therapy. The treatment works particularly well in interferon-sensitive patients who have lower fibrosis scores, according to a new study in the June issue of Hepatology, a journal published by John Wiley & Sons on behalf of the American Association for the Study of Liver Diseases (AASLD).

Nearly half of all HCV patients do not respond to the standard therapy of pegylated interferon and ribavirin. They remain at risk for developing life-threatening liver disease. So far, other alternative therapies have not been particularly successful in these nonresponders.

One new treatment with the potential to help patients with persistent HCV involves high doses of daily consensus interferon (CIFN) combined with ribavirin. Researchers, led by Bruce Bacon of St. Louis University, conducted a multicenter trial to examine the efficacy, tolerability and safety of this approach.

The researchers studied 487 patients whose HCV had not responded to initial treatment with standard therapy. Many had characteristics that generally bode poorly for treatment response. Nearly all had HCV genotype 1; 80 percent had not responded strongly to their previous treatment; 68 percent had high baseline levels of the virus in their blood; 60 percent had advanced liver disease; and about 20 percent were African-American. These factors have all been shown to reduce rates of sustained viral response after treatment.

The patients were divided into three groups. Two would receive the new therapy at different doses, and the third would receive no therapy. After 24 weeks, the control group was stratified into one of the treatment arms.

Ultimately, 245 of the patients received 9 mcg of CIFN daily along with ribavirin, and 242 others took 15 mcg of CIFN daily along with ribavirin. After 24 weeks, patients with detectable HCV RNA were considered non-responders and stopped the therapy. Responders continued taking their therapy up through week 48, and were then followed-up through week 72. If HCV RNA was detected between weeks 48 and 72, the patient was classified as a relapser.

Nearly 7 percent of the patients taking 9 mcg of CIBN, and 10.7 percent of those taking 15 mcg, achieved a sustained viral response. The rates were even higher among patients who had responded better to the standard therapy and among those who had lower baseline fibrosis scores.

"The best response rate, 31.6 percent, was observed in noncirrhotic patients who had a partial virologic response with a greater than 2-log10 decline in HCV RNA during their previous course of peg-IFN treatment," the authors report.

While adverse events were common, most patients continued their treatment in spite of them. Common side effects were neutropenia, fatigue, leucopenia, depression, nausea, muscle pain, lymphopenia and anemia.

"The present study demonstrated that some patients with chronic hepatitis C who have failed to respond to treatment with peg-IFN and RBV can be successfully retreated with daily CIFN and RBV," the authors conclude. "The greatest SVR rate during retreatment in the present study was observed in F0-F3 patients who had a partial virologic response during their prior course of treatment."


'/>"/>

Contact: Sean Wagner
medicalnews@bos.blackwellpublishing.com
781-388-8550
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. New treatment effective in counteracting cocaine-induced symptoms
2. New treatment boosts muscle function in myasthenia gravis
3. Broad-based group of physicians calls for improvement in stroke treatment
4. Cranberry Could Juice Up Ovarian Cancer Treatment
5. Non-medicinal treatment touted for pre-schoolers with ADHD
6. Nonmedicinal treatment touted for preschoolers with ADHD
7. U of M study: Early treatment can reverse heart damage
8. Biologic treatment for rheumatoid arthritis and the risk of cancer
9. New Treatment Explored for Cluster Headaches
10. Thailand: Partners Open Free AIDS Treatment Clinic in Renowned AIDS Temple in Lop Buri
11. 4-Star Gen. Barry Mccaffrey, Former U.S. Drug Czar, to Keynote Recovery Happens! Rally for Treatment: Wed., Sept. 5, 11 Am, State Capitol West Steps, Sacramento
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... York, NY & Greenwich, CT (PRWEB) , ... March 01, 2017 ... ... many runners, especially in the winter months when people don’t want to stop training ... the knees – and setting the treadmill to a small incline can help protect ...
(Date:3/1/2017)... ... , ... “McFarnia”: a suspenseful tale of a father who vanishes without a ... disappearance. “McFarnia” is the creation of published author Tony Pierzchala, a former Army man, ... a Chaplain with Transport for Christ at a truck stop in the Greensboro area. ...
(Date:3/1/2017)... ... ... of Love”: a tale of young love and war. ““Letter of Love”” is the ... Salvador, wife, mother, and co-founder of a Christian College. , “I turned to ... poor communities, and I study psychology. I lived the civil war. ” --Maria Teresa ...
(Date:3/1/2017)... ... , ... “The Affair is Over Now Go Live Your Life Abundantly”: a ... affair. “The Affair is Over Now Go Live Your Life Abundantly” is the creation ... dedicated her professional life to teaching and writing about marriage and family life in ...
(Date:2/28/2017)... ... , ... Answering strong demand for its medical device software design and development ... in the Soma neighborhood in San Francisco on March 1, 2017. The opening also ... systems architecture subject matter experts. , Orthogonal serves a sizeable clientele in the Bay ...
Breaking Medicine News(10 mins):
(Date:3/1/2017)... DIEGO , March 1, 2017  Aethlon ... European Patent Office has granted European Patent Number ... In recent years, exosomes have emerged ... a wide range of disease conditions, including cancer, ... (CTE).  This granted European Patent is an important ...
(Date:3/1/2017)... 1, 2017  Numotion, the nation,s leading provider of ... Tek RMD ("robotic mobilization device") by Matia Robotics in ... is a motorized standing movement device that offers the ... to complete everyday activities from a standing position. Unlike ... RMD unassisted. Numotion is the exclusive distributor of the ...
(Date:3/1/2017)... ... and Markets has announced the addition of the "Global Infertility ... The Global Infertility Therapy Partnering Terms and Agreements since 2010 ... into by the world,s leading healthcare companies. The report ... discovery or development stage whereby the licensee obtains a right or ...
Breaking Medicine Technology: